Further notifications

Here you find further notifications about Fraunhofer ITMP based on links to external websites.

News / 14.6.2023

Integrating Health Data to aid Clinical Decision-making for Lung Cancer Patients

The newly formed IDERHA consortium, consisting of academia, industry, health authorities, clinicians, and patient representatives, addresses the obstacles in accessing, integrating and analysing health data to maximize their value for patient care and research. Focusing on lung cancer, IDERHA wants to use com-plex digital health data to improve patient health outcomes by enabling more personalized care.

News / 6.6.2023

Hamburg and Marseille fight antimicrobial resistance together

The increasing resistance of bacteria against antibiotics represents a major threat for human health. On May 25 the University of Aix-Marseille, the Universität Hamburg and Fraunhofer ITMP signed a Memorandum of Understanding in Marseille to jointly develop novel drugs that eliminate resistance mechanisms in bacteria and thereby improve the efficacy of antibiotics.

News / 15.2.2023

Podcast on the "4D Clinic - Interdisciplinary Help for People with Immune Diseases"

Immune diseases, such as rheumatism or psoriasis, are systemic diseases that often affect several organ systems simultaneously. An interdisciplinary approach is absolutely necessary for the optimal care of patients. This is implemented at Fraunhofer ITMP in the concept of the 4D Clinic. Professor Frank Behrens, deputy director of the institute, describes in the Fraunhofer podcast why the 4D Clinic is unique and what the concept can achieve for patients and research.

News / 19.10.2022

The right prevention, diagnosis and therapy with a click of a mouse: that is the vision of the MED²ICIN lighthouse project

A digital patient model as the basis for personalized treatment of chronic diseases - Fraunhofer's MED²ICIN dashboard helps medical staff in day-to-day clinical and practice work to gain a quick overview of the patient file. PD Dr. med. Irina Blumenstein, specialist for internal medicine, gastroenterology and nutritional medicine at the University Hospital Frankfurt am Main, reports on her experiences.

News / 14.10.2022

Successful first round of the »TheraNova« Summer School

The first Summer School of the Innovation Center »Innovative Therapeutics« (TheraNova) took place in Mainz, October 13 to October 14, 2022. Project updates were given by participating PhD students and clinician scientists from Johann Wolfgang Goethe University and the Fraunhofer Institutes ITMP and IGD, and invited speakers highlighted current developments in the fields of innovative therapeutics, personalized medicine and entrepreneurship.

Press Release / 26.9.2022

Opening of the Fraunhofer ITMP-TNM Early Clinical Trial Unit (ECTU)

The Fraunhofer Institute for Translational Medicine and Pharmacology ITMP opened an Early Clinical Trial Unit (ECTU) at the University Medical Center Göttingen (UMG) on September 15, 2022. The focus is on first clinical testing of compounds for the treatment of largely intractable (autoimmune) diseases of the central nervous system (CNS), such as multiple sclerosis or Parkinson's disease. The goal is a rapid and targeted implementation of scientific findings to diagnostics, therapies and prevention.

Press Release / 22.9.2022

Opening of the Fraunhofer ITMP and awarding of the Fraunhofer medal to former premier of the state of Hesse Volker Bouffier

On September 21, 2022, the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP was officially opened. The institute, which was already transferred to an independent Fraunhofer Institute at the beginning of last year, has since developed into an important component and leading institute of Fraunhofer health research. During the opening ceremony at the University Hospital Frankfurt, Volker Bouffier was also honored with the Fraunhofer Medal.

News / 8.4.2022

Fraunhofer ITMP Spin-Off "Phialogics" Wins Sanofi "Golden Tickets" Competition

 

"Phialogics", the barely six-month-old spin-off of the Frankfurt site of the Fraunhofer ITMP, wins Sanofi's "Golden Tickets" competition. This enables the Fraunhofer spin-off to stay free of charge for one year at BioLabs in Heidelberg, which is becoming a hotspot for start-ups based on a concept imported from the USA.

"Transkript.de" reports on Phialogics and its success in the "Start-up of the Week" section.

News / 1.4.2022

After the virus is before the virus - Interview on the new Fraunhofer ITMP site in Munich/Penzberg

 

In mid-April, the first scientists of the Fraunhofer ITMP in Penzberg start work in rented laboratory space at Roche. The new center for Immunology, Infection and Pandemic Research is expected to be ready in 2-3 years. Süddeutsche Zeitung interviewed Gerd Geißlinger, head of the institute, and Michael Hoelscher, head of the Munich/Penzberg site, about the purpose of the future center: A conversation about new viruses and why diseases can be stopped with "4D".

Press Release / 20.1.2022

SARS-CoV-2 infection route via brain vessels identified

 

Neurological complications associated with COVID-19 occur frequently. Although the SARS-CoV-2 virus has already been detected in the brain tissue of patients, its routes of entry and the resulting consequences are not well understood. A team of researchers from Fraunhofer ITMP and the University Medical Center Hamburg-Eppendorf (UKE) has now shown that cells of the blood-brain barrier (BBB) can be infected in vitro by the SARS-CoV-2 pathogen and that this can be attenuated pharmacologically.

Press Release / 17.12.2021

New drug shows promise for the treatment of chronic spontaneous urticaria

 

Patients with chronic spontaneous urticaria are severely impaired in their quality of life. Unfortunately, standard therapy with antihistamines is not efficacious in many affected patients. However, these patients can now have hope. A new clinical trial with the participation of Fraunhofer ITMP in Berlin shows promising results for the efficacy of a new drug.

News / Press Release / 2.12.2021

Funding for the LOEWE centers DRUID and TBG extended

 

Fraunhofer ITMP is a partner of the LOEWE centers DRUID (Novel Drug Targets against Poverty-Related and Neglected Tropical Infectious Diseases) and TBG (Translational Biodiversity Genomics). Following the successful completion of the start-up phase, both LOEWE centers will now continue to receive funding from the state of Hesse in their operational phase and will receive project and construction funding totaling approximately 34.4 million euros for the duration of three years.

News / Press Release / 23.11.2021

The EU invests in a promising new COVID-19 therapy

 

The COVend research project aims to deliver a new therapy against COVID-19 that prevents the severe stages of the disease. Fraunhofer ITMP is one of the partners of the multidisciplinary consortium, which unites 17 partners from 13 European countries with expertise from different disciplines, including (cell) biology, ICT expertise for AI based evaluations, pharma, economics, and social sciences, as well as clinical expertise. 

News / Press Release / 2.11.2021

Fraunhofer Institutes present the first prototype for digital twins of patients

 

Optimum prevention, diagnosis and treatment in just one click: As part of the “MED²ICIN” lighthouse project, seven Fraunhofer Institutes, among them Fraunhofer ITMP, are presenting the first prototype of a digital patient model. This prototype revolutionizes the very foundation of personalized and cost-optimized treatment, opening up new perspectives. It has already been tested at University Hospital Frankfurt.

News / 29.10.2021

Honorary Doctorate for Prof. Jennifer Dressman

 

 

The University of Southern Denmark (SDU) awards honorary doctorates to researchers whom the University wishes to honour for their scientific work. As part of the annual University Celebration on October 29, 2021, Fraunhofer ITMP employee Prof. Jennifer Dressman received an honorary doctorate from SDU's Faculty of Science for her work on the pharmaceutical ecosystem.

News / 12.8.2021

Fraunhofer ITMP employee worldwide "psoriatic arthritis expert"

 

PD Dr. Frank Behrens, Deputy Director of Fraunhofer ITMP and Head of the Clinical Research division, is listed as an expert in psoriatic arthritis on the Expertscape expert platform. This places him in the top 1% of scientists worldwide who have written on the topic of psoriatic arthritis in the last 10 years. 

Expertscape uses PubMed-based algorithms to objectively rank individuals and institutions according to their expertise in more than 29,000 biomedical topics.

News / 12.5.2021

Drug Repurposing as strategy in the fight against COVID-19

 

After the recent successes in vaccine development, drug development against the COVID-19 disease is moving into focus. Fraunhofer ITMP is applying Drug Repurposing strategies in various projects focusing on SARS-CoV-2. Repurposing strategies use substances that have undergone clinical testing in other disease indications and investigate their effect against COVID-19. These strategies can not only identify effective substances for different stages of the disease, but also contribute to a better understanding of the mechanisms of action of this disease. 

News / 26.4.2021

iCAIR® delivers first results in the fight against Sars-CoV-2

 

Fraunhofer ITMP is a temporary project partner for the additional research project focussing on the development of inhalable drugs to combat SARS-CoV-2, started in May 2020 within the frame of the international iCAIR® consortium. The iCAIR® research team, coordinated by Fraunhofer ITEM, can already report promising results for this project.